Clinical Trial

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-04-28; most recent amendment 2026-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-09-08
Trial Details
NCT Number NCT06959511
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Exelixis
Conditions Neoadjuvant Treatment, Thyroid Cancer
Enrollment 45 participants
Start Date 2025-07-22
Primary Completion 2028-03-01 (estimated)
Study Completion 2030-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-28